Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients

Sci Rep. 2021 Sep 28;11(1):19251. doi: 10.1038/s41598-021-98749-4.

Abstract

The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.

MeSH terms

  • Aged
  • COVID-19*
  • Cohort Studies
  • Comorbidity*
  • Hospitalization
  • Humans
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Mortality
  • Prevalence
  • Prognosis*
  • Pulmonary Disease, Chronic Obstructive* / physiopathology
  • Risk Factors
  • Smoking / adverse effects*